Trial Profile
A Single-center, Open Label, Phase II Study of Anlotinib as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Jun 2019
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 14 Jan 2019 Status changed from not yet recruiting to recruiting.
- 10 Aug 2018 New trial record